Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Medically reviewed by Jordana Haber Hazan, MD Hemolytic anemia occurs when red blood cells are destroyed faster than they can ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.

SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in the American Journal of Hematology from the open label, ...

Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Chief Medical Officer, Global Head of Development at Sanofi “This ...

Babesiosis, a tickborne zoonotic disease caused by intraerythrocytic protozoa of the genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatment and ...

Autoimmune hemolytic anemia (AIHA) is a rare but clinically significant disorder in which the immune system mistakenly produces autoantibodies against red blood cells, leading to accelerated ...

Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia — a condition in which you have inadequate red blood cells due to premature destruction of those cells by your own immune ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

Noncancerous blood disorders are conditions that affect blood cells, such as red blood cells, white blood cells, and platelets. Blood disorders may cause symptoms and complications, but most are ...